Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.
Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems. The company also supplies laboratory instrumentation for process development, such as cell counting devices, automated liquid handling systems and critical cleaning and sterilization equipment. A focus on single‐use technologies has allowed customers to reduce the risk of contamination, shorten production timelines and enhance operational flexibility.
Founded as part of the Sartorius Group, Sartorius Stedim Biotech traces its roots to the 1870 establishment of Sartorius AG in Germany, with the Stedim Biotech subsidiary later integrated to form a dedicated bioprocess solutions business. Headquartered in Aubagne, France, the company has production and research facilities across Europe, North America and Asia‐Pacific. Its global network of sales and service centers ensures technical support and training for biopharmaceutical manufacturers at every stage of the production lifecycle.
Sartorius Stedim Biotech’s growth strategy emphasizes investment in research and development, strategic acquisitions and expansion of its single‐use portfolio. By collaborating with industry and academic partners, the company aims to drive innovation in bioprocessing, accelerating the delivery of life‐saving therapies to patients worldwide.
AI Generated. May Contain Errors.
